Launched in December 2003, the AMDS is a network created to expand access to quality, effective treatments for HIV by improving the supply of antiretrovirals (ARVs) and diagnostics to developing countries. In 2014, tracking procurement of hepatitis commodities was added to the portfolio, and recently in 2020 AMDS started also working on STI medicines and diagnostics.

The main outputs of AMDS are:

• developing strategic information on HIV, hepatitis, and STI drugs and diagnostics;
• publishing annual market sizes and forecasting global demand for HIV, hepatitis and STI medicines and diagnostics; and
• supporting capacity-building activities for health supply chains.

The strategic information work conducted by the AMDS network focuses on the sources, prices, procurement, regulatory status and availability of the active pharmaceutical ingredients for HIV, hepatitis and STI drugs and diagnostics. AMDS also focuses on the sources and prices of methadone and buprenorphine (used in opioid substitution treatment) and of drugs used to treat HIV opportunistic infections.